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Abstract
Purpose: To evaluate feasibility and outcome of our institutional SIB-IMRT schedule in patients with anal cancer
and to selectively review the literature on different SIB-IMRT schedules.
Patients and methods: Between 01/08-06/13 25 patients with biopsy proven squamous cell anal cancer were
treated in our institution with IMRT. Radiotherapy was delivered in two series using a SIB-IMRT schedule of
45 Gy/1.8 Gy to the primary tumor and adjacent pelvic lymph nodes and 38 Gy/1.52 Gy to elective nodes followed
by an IMRT boost of 7×2 Gy = 14 Gy to the primary tumor and involved nodes (cumulative prescription dose: 59 Gy).
Results: Mean follow-up was 20 months (range: 4-68). The 2-year-local control, colostomy-free survival, distant
metastases-free survival and overall survival rates were 92%, 92%, 92%, and 88%, respectively. Grade 3 acute skin
toxicity was observed in 6 patients (24%). No high grade gastrointestinal or urinary acute toxicity occurred. Four
patients required more than one day of treatment interruption due to acute toxicity. No grade 3 or higher late
sequelae were observed.
Conclusion: We present our institutional SIB-IMRT experience treating patients with anal cancer in two series using
moderate single doses from 1.5-2.0 Gy. Our results, in terms of loco-regional outcome and toxicity, were comparable
to other studies. The incidence of treatment interruptions was very low. Therefore this schedule appears to be safe
for clinical use.
Keywords: SIB-IMRT, Anal cancer, Definitive radio-chemotherapy
Introduction
Anal cancer is rare with an incidence of only 1-2/
100.000 [1]. Since Nigro et al. observed high rates of
response in the neoadjuvant setting, organ preserving
definitive radio-chemotherapy has been the standard of
care [2]. Randomized phase III trials confirmed superiority
of concurrent radio-chemotherapy using 5-fluorouracil
(5-FU) and mitomycin C (MMC) compared to radio-
therapy alone [3,4] or platinum-based radio-chemotherapy [4].
The loco-regional control rates of patients treated with
radio-chemotherapy in randomized phase III trials ranged
from 61% to 84% after 5 years [3-5]. In RTOG 98-11
major acute G3 or higher toxicities were skin reactions
(49%), hematologic effects (61%), and gastrointestinal
toxicities (37%). Major late G3 or higher toxicities were
skin reactions (3%) and gastrointestinal problems (3%) [5].
So far, all prospectively randomized phase III studies on
radiation therapy of anal carcinoma used 3-D conformal
radiotherapy [3-5]. In recent years, several multi- and
single institution studies demonstrated that intensity-
modulated radiotherapy (IMRT) reduced toxicity with-
out compromising outcome [6-12]. The use of highly
conformal IMRT for treatment of anal cancer is attract-
ive because of the large treatment volumes adjacent to
the small bowel and bladder as well as exposure of the
skin in the gluteal fold to high doses. A recent prospect-
ive RTOG phase II trial (RTOG 0529) investigated the
utility of IMRT in anal cancer. The 2-year loco-regional
control rate was 80%. In comparison to the results of
RTOG 98-11 the use of IMRT reduced early G3 or
higher gastrointestinal toxicity from 36% to 22%, and G3
or higher skin toxicity from 47% to 20% [13]. However,
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until long term control rates become available, concerns
remain regarding potential compromise of tumor control
rates using more conformal radiotherapy. IMRT can be
delivered in several consecutive series using cone-down
boost technique but also offers the possibility to deliver
treatment giving different doses to different target
volumes at the same time (simultaneously integrated
boost (SIB) or “dose painting”). The optimal technique of
IMRT with or without SIB is still under debate, because
the use of a SIB requires altered fractionation schedules
that might compromise tumor control, if too low dose
per fraction is used, or increase toxicity if doses above 2
Gy fractions are used. Up to date no standard SIB IMRT
schedule has been established.
Here we present the outcome of 25 anal cancer patients
treated consistently with our institutional SIB-IMRT
schedule. Additionally we undertook a selective litera-
ture review on clinical studies investigating different
SIB-IMRT schedules for treatment of patients with anal
cancer.
Patients and methods
Patients
From 01/2008 to 06/2013 25 patients with biopsy proven
squamous cell anal cancer were included in the analysis
(Table 1).
All patients alive at the time of analysis were contacted
by telephone (S.J.) or were recently seen in our depart-
ment for regular follow-up visits. Additional information
was obtained from general practitioner and attending
specialist. Patient and treatment related parameters are
summarized in Tables 1 and 2.
SIB-IMRT
All patients underwent a planning-CT in supine position.
Gross tumor volume (GTV) was defined as macroscopic
disease (primary with/without lymph nodes). Elective
node regions such as inguinal and iliacal, obturator and
presacral lymph nodes were delineated as clinical target
volumes (CTV). The GTV was expanded by at least 2 cm
and the CTV by 1 cm for the planning target volume
(PTV). A second planning CT was performed around
40 Gy for definition of the boost volume. The boost PTV
usually contained a margin of at least 2 cm from the
primary tumor and 1-2 cm from the nodal GTV.
SIB-IMRT was performed using the following institu-
tional standard schedule:
1st series: 45 Gy in 1.8 Gy single doses to the pelvis,
involved lymph nodes (PTV1) and lymph nodes at high
risk for microscopic disease (usually lower internal and
external iliac nodes) and 38 Gy in 1.52 Gy single doses
to elective nodes (PTV2). Elective nodes were mainly
uninvolved inguinal and upper internal iliac nodes.
2nd series: IMRT boost of 7×2 = 14 Gy given to the pri-
mary tumor and lymph node metastases (total prescrip-
tion dose: 59 Gy). In 2 patients with low risk tumors the
Table 1 Patient related parameters
Age
Mean age (years) 61
Range 41-90
Gender
Male 16 (64%)
Female 9 (36%)
Tumor stage
T1 3 (12%)
T2 12 (48%)
T3 8 (32%)
T4 2 (8%)
Nodal stage
N0 13 (52%)
N1 6 (24%)
N2 4 (16%)
N3 2 (8%)
Distant metastases
M0 25 (100%)
M1 0 (0%)
Table 2 Treatment related parameters
Postoperative IMRT 2 (8%)
Definitive IMRT 23 (82%)
RT dose
Series 1 SIB: 45 Gy SIB 25 (100%)
IMRT (25x1.8/1.52 Gy)
Series 2 Boost:
7x2 = 14 Gy (total: 59 Gy) 20 (80%)
7x2.1 = 14.7 Gy (total: 59.7 Gy) 1 (4%)
8x1.8 = 14.4 Gy (total: 59.4 Gy) 1 (4%)
6x1.8 = 9.8 Gy (total: 55.8 Gy) 1 (4%)
5x1.8 = 9 Gy (total: 54 Gy) 2 (8%)
Treatment breaks >1 day 4 (16%)
Concomitant chemotherapy (5-FU and MMC) 21 (84%)
Mean treatment volumes (ccm, range)
GTV 33.2 (6-103)
PTV38 Gy 1042.9 (248-3222)
PTV45 Gy 1483.3 (482-2874)
PTV59 Gy 335.1 (56-666)
IMRT: intensity modulated radiotherapy, SIB: simultaneously integrated boost,
GTV: gross tumor volume, PTV: planning target volume.
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boost was reduced on an individual basis to a total dose
of 54 Gy (Figure 1).
For treatment planning, the dose was normalized to
the mean dose in PTV1. For intensity optimization, the
prescribed dose encompassed at least 95% of the PTV.
Additionally, no more than 2% of any PTV received >110%
of its prescribed dose, whereas no more than 1% of any
PTV received <93% of the prescribed dose. Irradiation was
delivered with four to five coplanar beam angles by a
6-MV dynamic MLC system (Varian Medical Systems,
Palo Alto, CA) using a sliding window technique, or using
volumetric modulated arc technique (VMAT, n = 19, since
10/2010).
Systemic therapy
Systemic therapy preferably consisted of concomitant 5-
fluorouracil (5-FU) day 1-5 (750 mg/m2, maximum ab-
solute dose: 1500 mg) and mitomycin C (MMC) day 1
(10 mg/m2, maximum absolute dose: 20 mg) in week
one and five (n = 21). In 5 patients, chemotherapy was
reduced or stopped after the first cycle due to blood
count changes and/or reduction of general condition.
Four patients did not receive any systemic therapy due
to age and/or reduced Karnofsky performance score
(n = 2) or postoperative setting (n = 2).
Assessment of toxicity
Acute and late toxicity was assessed according to the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0.
Statistical analysis
Kaplan Meier survival analyses were performed using
SPSS version 21.
Analysis was approved by the ethics committee of the
Zurich university hospital.
Results
Disease control
The mean follow-up time was 20 months (range: 4-68).
The 2-year local control, disease free survival, colostomy-
free survival, metastasis-free survival and overall survival
rates were 92%, 92%, 92%, 92% and 88%, respectively
(Figure 2).
At the time of analysis, 3/25 (12%) patients were dead.
In two cases this was tumor related due to primary
tumor progression (n = 1) or distant metastases (n = 1),
whilst the third patient died from a progressive lung
cancer.
An 86 year old patient with a stage T2N0G3 cancer
treated with chemoradiation to 59 Gy developed a local
recurrence 10 months after RT completion. A salvage
Figure 1 SIB-IMRT plan. (A) SIB-IMRT plan for a 47-year old male anal cancer patient (cT2cN0M0). Light green: 38 Gy, blue: 45 Gy pelvis field.
(B) IMRT boost volume, second series to the tumor. Yellow: 14 Gy. Pink: GTV.
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colostomy was carried out. The patient is still alive and
free of disease. A 61 year old female patient with a stage
T3N0G2 cancer treated with chemoradiation to 59 Gy
suffered from tumor persistence and died 21 months
after RT completion due to reduced general condition/
local and distant tumor progression. One patient deve-
loped lung metastases three months after completion of
radio-chemotherapy and died due to distant tumor
progression after 3 months.
Early radiation induced side effects
Grade 3 acute skin toxicity was observed in 6 pa-
tients (24%) and grade 3 acute hematologic toxicity in
4 patients (16%). No other grade 3 or higher acute tox-
icity was seen. If only patients with radio-chemotherapy
were considered acute grade 3 skin and hematologic
toxicity was seen in 5/21 (24%) and 4/21 (19%),
respectively. 15 patients had no treatment breaks. Six
patients had one single day of therapy interruption, 2
Figure 2 Survival curves. A-D: Overall survival, colostomy-free survival, distant metastases free survival, loco-regional control, FU=follow-up.
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patients 2 days and one patient missed 3 and 4 days,
respectively.
Late tolerance
Late toxicity was reported as grade I proctitis in one
patient 18 months post IMRT completion, one patient
suffered from intermittent diarrhea 14 months after
completion of radio-chemotherapy and another patient
had a slight insufficiency of sphincter muscle (22 months
after IMRT). No grade 3 or higher late sequelae were
observed.
Discussion
Patients with anal cancer have been treated with organ
preserving radio-chemotherapy since the findings of
Nigro et al. [2]. Radio-chemotherapy is superior to ra-
diotherapy alone [3]. Efforts to replace MMC by cispla-
tin have not been beneficial in terms of tumor control
[5]. As loco-regional control rates of up to 84% at 5 years
are acceptable, a major focus is reduction of treatment
related side effects which have been remarkably high
with acute ≥ grade 3 hematologic toxicity of 26%/61%,
skin reaction of 48%/49% and gastrointestinal toxicity of
16%/37% in UK anal cancer trial (ACT II) and RTOG
98-11, respectively [5,14].
IMRT is a technique to deliver radiotherapy with mo-
dulated beams holding the chance to deliver highly con-
formal doses to the target volume while sparing organs
at risk. Several series beginning in the early 2000`s
reported their experiences with IMRT in anal cancer
treatment.
Side effects
Studies comparing results of patients treated with IMRT
and 3-D plans identified reduced major acute and late
non-hematological toxicities without a compromise in
outcome [6,7,9]. As an example, Chuong et al. found
a reduction of acute ≥G3 non-hematologic toxicity of
almost 40% (p = <.0001). Menkarios et al. and Brooks
et al. showed a significantly reduced dose to small bowel,
bladder and genitalia compared to 3-D planning [10,11].
The study groups of Salama and Kachnic evaluated
IMRT in comparison with historic standards and con-
firmed significant reduction of acute and late toxicity
[8,13]. In the RTOG 0529 phase II IMRT study, there
was a significant reduction of acute grade 2+ hematologic
(73% vs. 85%), grade 3+ gastrointestinal (21% vs. 36%) and
grade 3+ dermatologic adverse events (23% vs. 49%) in
comparison to the results of RTOG-98-11 [15]. In terms
of efficacy and toxicity our results also compare favo-
rably with the randomized trials using 3-D-conformal
techniques and are comparable to recent IMRT studies
(Table 3). Before the IMRT era anal cancer patients in our
institution were treated with 3-D conformal 45 Gy to the
pelvis plus 14.4 Gy photon boost or 14 Gy high dose rate
brachytherapy with Ir192 (in 7 fractions). In published
results of 81 patients overall acute grade 3 or 4 toxicity of
43% (photon boost) and 15% (brachytherapy boost) was
observed. Chronic toxicity occurred in 19% (brachyther-
apy boost) and 30% (photon boost) [16]. In the current
IMRT series we observed acute grade 3 skin toxicity in
only 24% of patients. Only 3 patients complained about
low grade late toxicity and no grade 3 or higher late
sequelae were seen. Response rates in both series are
comparable.
Treatment breaks
In comparison to other published results, the treatment
breaks in our patient cohort were considerably low with
only 8% of patients in need of more than 1 day of treat-
ment break due to acute toxicity. These data reflect the
good tolerability of our approach. Salama et al. found
breaks in 41.5% of patients, lasting a median of 4 days
[8]. Bazan et al. reported on 34.5% treatment breaks with
IMRT, which was significantly less than with 3-D plan-
ning (88%) [7]. In RTOG 98-11, treatment breaks were
reported in 62% and were mainly required secondary to
radiation toxicities. One reason for low acute skin
toxicity in our patients could be sophisticated nursing
with specially trained nursing staff provided in our out-
patient clinic. As treatment breaks are shown to com-
promise treatment outcome in anal cancer patients
[17,18], this is an important finding.
SIB-IMRT in anal cancer patients
IMRT, in principle, enables delivery of different doses to
different target volumes (e.g. pelvic and inguinal lymph
nodes) in the same treatment session (SIB, “dose paint-
ing”). This leads to a shortening of the treatment course.
In addition, only one or two physic plans have to be gener-
ated and approved. There is still concern regarding the
use of a SIB technique in anal cancer because more
conformal dose distribution and altered dose per fraction
might compromise outcome and/or increase toxicity.
As summarized in Table 3, several different SIB IMRT
schedules are described in the literature. In some stud-
ies, the total dose varied according to T stage [12,13].
Most studies administered SIB in only one series whereas
4 studies conducted 2 series [7,8,10,19]. SIB dose per frac-
tion ranged from 1.28 Gy to 2.25 Gy and total doses from
30.6 Gy to 59.4 Gy. When we implemented IMRT in anal
cancer, we decided to deliver SIB-IMRT carefully in 2
series with single fractions of maximally 2 Gy, because we
did not want to risk increased toxicity. In comparison to
many US centers and the RTOG trials, in which 45 Gy/
50.4 Gy were given to T1/T2 and 55-59 Gy/54 Gy to T3/4
Janssen et al. Radiation Oncology 2014, 9:199 Page 5 of 9
http://www.ro-journal.com/content/9/1/199
Table 3 Different SIB-IMRT schedules in treatment of anal cancer
Study/year Patients Mean FU
(months)
SIB-IMRT dose levels
(prescription total dose/single dose)
Number
of series
Range of
SIB-single dose
DFS LRC CFS OS Acute ≥ grade 3 toxicity
Menkarios 2007 5 * Concept: 2 dose levels (SIB): 1-2 1.5-1.8 Gy * * * * *
49.5/1.5 Gy
59.4/1.8 Gy
or
2 series (45/1.8 and 59.4/1.8 Gy)
Salama 2007 53 14.5 PTV: 32-60.9 Gy (median: 51.5 Gy) 1-2 1.65-2.0 Gy 84%/1.5y 84%/1.5y 93%/1.5y GI: 15%
Skin: 38%
ENI: 30.6-45 Gy (median: 45 Gy) Hematologic: 59%
Concept: 3 dose levels:
41.25/1.65 Gy,45/1.8, 50/2.0 (+/-boost)
Vieillot 2010 10 * Concept: 2 dose levels: 1 1.5-1.8 Gy * * * * *
49.5/1.5 Gy
59.4/1.8 Gy
Call 2011 34 22 PTV: 48.6-57.6 Gy (median: 50.4 Gy) 1 1.28-2.25 Gy 80%/3y 87%/3y Not reported
ENI: 38-45 Gy
No standard concept
Barzan 2011 29 32 Concept: 3 dose levels: 2 1.6-1.8 Gy 92/3y 91/3y 88%/3y GI: 7%
Skin: 21%40/1.6 Gy
45/1.8 Gy Hematologic: 21%
+boost 5.4 Gy (T1/2), 9-14.4 Gy (T3/4)
Kachnic 2012 43 24 Concept: T-stage based SIB (2 dose levels) 1 1.5-1.8 Gy 95%/2y 94%/2y 92%/2y GI: 7%
Skin: 10%
T2N0: 42/1.5 Gy ENI, 50.4/1.8 Gy to PTV Hematologic: 51%
T3-4N0-3: 45/1.5 Gy ENI,
50.4/1.68 Gy to lymph nodes<3cm
54/1.8 Gy to PTV and lymph nodes>3cm
Deenen 2012 18 28 49.5/1.5 Gy ENI 1-2 1.5-1.8 Gy 83%/2y GI: 0%,
59.4/1.8 for PTV Skin: 50%
Boost 5.4/1.8 Gy for macroscopic residual tumor after 5 weeks Hematologic: 0%
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Table 3 Different SIB-IMRT schedules in treatment of anal cancer (Continued)
Mitchell 2013 65 19 PTV: 50-58.8 Gy (median: 54 Gy) 1 1.62-2.0 Gy 86%/2y 96%/2y GI: 9%
Skin: 17%
ENI: 40.5-50.4 Gy (median: 45 Gy) Hematologic: 3%
Concept: T-stage based SIB (2 dose levels):
T1: 50/2 Gy, 43/1.72 Gy
T2: 54/2, 45/1.67 Gy
T3/4: 58/2 , 47/1.62 Gy
Present study 25 20 45/1.8 Gy to PTV 2 1.52-2 Gy 92%/2y 92%/2y 92%/2y 88%/2y GI: 0%,
38/1.52 Gy ENI Skin: 23%
14/2 Gy boost to PTV in second series (total: 59 Gy) Hematologic: 16%
*comparison of different plans, ENI = Elective node irradiation, FU = Follow-up, GI = Gastrointestinal, PTV = Planning target volume.
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tumors (RTOG 98-11, RTOG 0529), we usually give 59 Gy
regardless of T stage with very few exceptions for very
small primary tumors.
In our opinion, the concept of two series has two
major advantages: Firstly, the single dose to elective
nodes is not below 1.52 Gy to 1.8 Gy and the dose to
the GTV can be kept at 2 Gy fractions. Secondly, the
boost holds the chance to escalate doses in 2.0 Gy single
doses on an individual basis. Limitations of our study
are its retrospective design, the limited number of
patients and short follow-up. However, we present an
easy to use SIB-IMRT schedule and our clinical data and
experience suggest that this schedule is safe and effica-
cious when compared to other published series.
Conclusion
We present a new SIB-IMRT schedule to treat patients
with anal cancer in two series using moderate single
doses from 1.5-2.0 Gy with a total dose of 59 Gy in
combination with 5FU/MMC. Our results, in terms of
loco-regional control and toxicity, are comparable to the
results of other studies. Remarkably, the incidence of
treatment interruptions was very low. Therefore this
schedule appears to be safe and favorable for clinical use.
More prospective studies on SIB-IMRT schedules are
needed in order to define a standard.
Informed consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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